Keyword: Tecentriq

Keytruda's U.S. NSCLC sales might start to fall as soon as early 2020, one analyst says, as I-O rivals eat into its share based on recent successes.

Combined with Avastin, Roche's IO med beat Bayer's standard-of-care Nexavar at stalling liver cancer progression—and helped patients live longer, too.

Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact."

Riding high on FDA and EU approvals in triple-negative breast cancer, Roche’s Tecentriq hoped for a win from NICE. The drugmaker didn’t get it.

If this year’s ASCO meeting was “quiet,” as some contended, this year’s ESMO was anything but.

Bladder cancer is a “difficult malignancy.” That’s how a Roche exec prefaced comments on data showing Tecentriq-plus-chemo narrowly beat chemo alone.

Merck won’t be stepping on Roche’s toes anytime soon in metastatic TNBC. But the New Jersey drugmaker says it learned from its phase 3 miss.

Teaming PD-1 immunotherapy Tecentriq with MEK-targeted Cotellic to treat melanoma was a decent idea. Too bad it didn't work out as planned.

Right now, Merck’s Keytruda is the only I-O treatment approved solo in previously untreated NSCLC. But Roche’s Tecentriq is looking to make it two.

Roche has been looking to capture lung cancer share from Merck with its chemo combo. And it's trying to bring its quest to the monotherapy arena, too.